Novartis' Trevor Mundel quits to join Gates Foundation
This article was originally published in Scrip
Effective from 1 December, Novartis' global head of development, Trevor Mundel, will leave the company to join the Bill and Melinda Gates Foundation as president of its Global Health Program. Mr Mundel has been a senior executive at Novartis since 2003. He is also on the boards of the Genomic Institute of the Novartis Research Foundation and the Novartis Venture Fund. Novartis plans to name a successor shortly.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.